Correspondence 0001193125-24-030359 from LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc.
Date: Feb. 9, 2024 · CIK: 0001815776 · Accession: 0001193125-24-030359
AI Filing Summary & Sentiment
File numbers found in text: 333-275919
Referenced dates: February 9, 2024
Letter
Goodwin Procter
The New York Times Building
620 Eighth Avenue
New York, NY 10018
VIA EDGAR
February 9, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3628
Attention: Doris Stacey Gama, Jason Drory, Eric Atallah and Lynn Dicker
Re: Graphite Bio, Inc.
Amendment No. 2 to Registration Statement on Form S-4
Filed February 5, 2023
File No. 333-275919
Ladies and Gentlemen,
On behalf of Graphite Bio, Inc. (the “Company”), we are submitting this letter to the Securities and Exchange Commission (the “SEC”) via EDGAR in response to the comment letter from the staff of the SEC (the “Staff”), dated February 9, 2024 (the “Comment Letter”), pertaining to the Company’s above-referenced Registration Statement on Form S-4 (the “Registration Statement”). In connection with such responses, the Company is concurrently filing Amendment No. 3 to the Registration Statement (the “Amended Registration Statement”).
For your convenience, the Staff’s comments are summarized in this letter, and each comment is followed by the applicable responses on behalf of the Company. Unless otherwise indicated, page references in the responses correspond to the page numbers in the Amended Registration Statement. Capitalized terms used in this letter but otherwise not defined herein shall have the meanings set forth in the Amended Registration Statement.
Amendment No. 2 to Registration Statement on Form S-4 filed February 5, 2024
Litigation Related to the Merger, page 23
1. Please provide the disclosures required by Item 103 of Regulation S-K, including, for example only, the relief sought.
Response: The Company respectfully acknowledges the Staff’s comment and advises the Staff that it has revised the disclosure on pages 31 and 310 of the Amended Registration Statement in response to the Staff’s comment.
*****
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
February 9, 2024
Page
Please contact the undersigned at (617) 570-1861 or via email at agoodman@goodwinlaw.com if you have any questions with respect to the foregoing.
Very truly yours,
/s/ Andrew H. Goodman
Show Raw Text
CORRESP 1 filename1.htm CORRESP Goodwin Procter The New York Times Building 620 Eighth Avenue New York, NY 10018 VIA EDGAR February 9, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Doris Stacey Gama, Jason Drory, Eric Atallah and Lynn Dicker Re: Graphite Bio, Inc. Amendment No. 2 to Registration Statement on Form S-4 Filed February 5, 2023 File No. 333-275919 Ladies and Gentlemen, On behalf of Graphite Bio, Inc. (the “Company”), we are submitting this letter to the Securities and Exchange Commission (the “SEC”) via EDGAR in response to the comment letter from the staff of the SEC (the “Staff”), dated February 9, 2024 (the “Comment Letter”), pertaining to the Company’s above-referenced Registration Statement on Form S-4 (the “Registration Statement”). In connection with such responses, the Company is concurrently filing Amendment No. 3 to the Registration Statement (the “Amended Registration Statement”). For your convenience, the Staff’s comments are summarized in this letter, and each comment is followed by the applicable responses on behalf of the Company. Unless otherwise indicated, page references in the responses correspond to the page numbers in the Amended Registration Statement. Capitalized terms used in this letter but otherwise not defined herein shall have the meanings set forth in the Amended Registration Statement. Amendment No. 2 to Registration Statement on Form S-4 filed February 5, 2024 Litigation Related to the Merger, page 23 1. Please provide the disclosures required by Item 103 of Regulation S-K, including, for example only, the relief sought. Response: The Company respectfully acknowledges the Staff’s comment and advises the Staff that it has revised the disclosure on pages 31 and 310 of the Amended Registration Statement in response to the Staff’s comment. ***** U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences February 9, 2024 Page 2 Please contact the undersigned at (617) 570-1861 or via email at agoodman@goodwinlaw.com if you have any questions with respect to the foregoing. Very truly yours, /s/ Andrew H. Goodman Andrew H. Goodman Goodwin Procter LLP cc: Kimberlee C. Drapkin, Graphite Bio, Inc. Maggie L. Wong, Goodwin Procter LLP Shoaib Ghias, Goodwin Procter LLP Tevia K. Pollard, Goodwin Procter LLP